证券代码：430047 证券简称：诺思兰德 公告编号：2024-027 北京诺思兰德生物技术股份有限公司 2023 年度独立董事述职报告（任自力） 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担个别及连带法律责任。 本人作为北京诺思兰德生物技术股份有限公司（以下简称"公司"）的独立 董事，2023 年度，本人严格按照《公司法》、《证券法》、《上市公司独立董事 管理办法》及《北京证券交易所上市公司持续监管指引第 1 号——独立董事》等 有关法律、法规及《独立董事工作制度》和《公司章程》的相关规定和要求，认 真履行独立董事职责，及时了解公司的经营状况，按时出席公司召开的相关会议 并认真审议各项议案，对公司重大事项发表了独立意见，充分发挥了独立董事的 作用，切实维护了公司和全体股东特别是中小股东的合法权益。现将本人 2023 年履职情况报告如下： 一、个人基本情况 本人现任北京航空航天大学法学院教授、北京市汉鼎联合律师事务所兼职律 师、北京仲裁委员会/北京国际仲裁中心仲裁员、深圳国际仲裁院仲裁员、北京 金融法院首批咨询专家、现任 ...

中审亚太会计师事务所（特殊普通合伙） China Audit Asia Pacific Certified Public Accountants LLP 审 计 报 告 AUDIT REPORT 北京诺思兰德生物技术股份有限公司 2023 年度财务报表审计 中国·北京 BEIJING CHINA 目 录 二、形成审计意见的基础 我们按照中国注册会计师审计准则的规定执行了审计工作。审计报告的"注 册会计师对财务报表审计的责任"部分进一步阐述了我们在这些准则下的责任。 按照中国注册会计师职业道德守则,我们独立于诺思兰德,并履行了职业道德方 面的其他责任。我们相信,我们获取的审计证据是充分、适当的,为发表审计意 见提供了基础。 | 一、审计报告 | 1-5 | | --- | --- | | 二、已审财务报表 | | | 1．合并资产负债表 | 6-7 | | 2．合并利润表 | 8 | | 3．合并现金流量表 | 9 | | 4．合并股东权益变动表 | 10-11 | | 5．资产负债表 | 12-13 | | 6．利润表 | 14 | | 7．现金流量表 | 15 | | 8．股东权益变动表 | 16-17 | ...

证券代码：430047 证券简称：诺思兰德 公告编号：2024-041 北京诺思兰德生物技术股份有限公司 关于 2023 年度权益分派的说明 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 北京诺思兰德生物技术股份有限公司（以下简称"公司"）于 2024 年 4 月 25 日召开第六届董事会第十次会议、第六届监事会第九次会议决议，审议通过 了《关于公司 2023 年度权益分派方案的议案》。公司本年不派发现金红利，不 送红股，也不进行资本公积转增股本。 现将有关事项公告如下： 一、权益分派预案情况 根据公司 2024 年 4 月 25 日披露的 2023 年年度报告（财务报告已经审计）， 2023 年公司归属于上市公司股东的净利润-4813.48 万元 ，母公司 2023 年度净利 润-5070.72 万元 ；截至 2023 年 12 月 31 日，公司合并报表未分配利润为-33670.63 万元，母公司报表未分配利润-30482.55 万元，母公司资本公积余额为 23409.06 万元。根据《公司法》《 ...

Share Issuance and Capital Structure - The company plans to issue up to 30,000,000 shares, raising a total of no more than RMB 230.8 million, primarily for drug development projects and working capital [5]. - The total share capital increased to 258,767,903 shares after the stock options exercise and restricted stock release [6]. - The controlling shareholders voluntarily agreed to a share lock-up period until December 31, 2026, reflecting confidence in the company's future [6]. - The company plans to issue 16,106,071 shares in January 2024, raising a net amount of ¥223,884,002.44 [23]. - The company has a total of 2,881,500 shares in stock options and restricted stocks that have been granted but not yet exercised or released from restrictions [142]. - During the reporting period, 1,049,700 shares of stock options were exercised, increasing the total share capital to 258,767,903 shares [143]. - The company has confirmed that the conditions for the second exercise period of stock options have been met, allowing for the exercise of options [146]. - The company anticipates that the stock option expenses will have a minor impact on net profit but will not affect cash flow from operating activities [145]. Financial Performance - The company's operating revenue for 2023 was ¥59,675,141.95, a decrease of 7.70% compared to ¥64,654,602.85 in 2022 [26]. - The gross profit margin for 2023 was 49.20%, down from 64.95% in 2022 [26]. - The net loss attributable to shareholders for 2023 was ¥48,134,821.42, compared to a profit of ¥67,616,828.07 in 2022 [26]. - Total assets at the end of 2023 were ¥328,120,719.02, a decrease of 4.96% from ¥345,231,281.15 at the end of 2022 [27]. - Total liabilities increased by 23.86% to ¥131,496,996.06 in 2023 from ¥106,169,377.54 in 2022 [27]. - The weighted average return on equity for 2023 was -27.02%, an improvement from -32.07% in 2022 [26]. - The company reported a significant decrease in cash inflows from sales and services due to changes in sales models and lack of tax refunds this period [79]. - The company reported a positive undistributed profit but did not propose a cash dividend distribution plan for the reporting period [174]. Research and Development - The company is focused on drug research and development, with significant investments planned for the upcoming year [5]. - The company has 11 biopharmaceutical projects in its R&D pipeline, including 5 gene therapy projects and 6 recombinant protein projects [36]. - The company has obtained 30 patent authorizations, including 25 domestically and 5 internationally [37]. - The company is prioritizing its R&D resources towards key projects NL003 and NL005, while temporarily halting the development of another project to optimize resource allocation [98]. - The company aims to develop a new drug for type 2 diabetes using GLP-1 gene therapy, which is currently in early evaluation [99]. - The company is also working on a recombinant FVIIa product for hemophilia patients, which could fill a market gap in China if successfully developed [99]. - The company is focusing on gene therapy for osteoarthritis, which is expected to provide a novel treatment option and enrich its R&D pipeline [100]. - The company reported R&D expenditure of ¥43,492,883.81, which is 72.88% of its operating revenue, down from 87.24% in the previous period [94]. Clinical Trials and Product Development - The clinical trial for the innovative drug NL003 for treating Rutherford grade 5 severe lower limb ischemia has completed enrollment [5]. - The company has completed the enrollment of all subjects for the clinical trial of NL003 for treating Rutherford grade 4 severe lower limb ischemia [5]. - The company has made significant progress in the clinical trials of its NL003 and NL005 projects, with all patient enrollments for the NL003 ulcer indication completed as planned [41]. - The company is currently in the third phase of clinical trials for a gene therapy product aimed at treating critical limb ischemia, which is expected to enhance its core competitiveness [98]. - A project for recombinant human thymosin β4 aimed at treating acute myocardial infarction is in the second phase of clinical trials, with potential for significant economic benefits upon successful development [98]. - The company is in the approval stage for a glaucoma treatment eye drop (NL411), which is expected to significantly increase sales revenue once approved [100]. - A new eye drop for presbyopia (NL303) is being developed, addressing a significant unmet clinical need in the domestic market [101]. - The company is developing a single-dose eye drop (RD401) for allergic conjunctivitis, which is expected to be safer for children and provide new revenue growth opportunities [102]. Market and Business Strategy - The company aims to enhance its market presence through the development of new biopharmaceuticals and expansion into new therapeutic areas [5]. - The company is actively researching commercialization strategies for its products, including the NL003 project, to facilitate market entry [44]. - The company is committed to expanding its product pipeline in gene therapy and recombinant protein drugs, targeting cardiovascular, metabolic, rare diseases, and ophthalmic conditions [119]. - The company is leveraging digital and intelligent methods to expedite the construction of its biopharmaceutical industrialization base [118]. - The company is actively engaging in collaborations with domestic and international pharmaceutical companies and research institutions to enhance its technological capabilities [121]. - The company is implementing a comprehensive marketing strategy to prepare for the commercialization of its biopharmaceutical products [120]. - The company is focusing on employee welfare and talent development to build a high-efficiency research and management team [121]. Operational Challenges and Risks - The company faces risks related to the lengthy and complex drug development process, with ongoing projects currently in clinical trial or preclinical stages [128]. - Uncertainties in macro policies, such as drug registration approval and healthcare insurance reforms, may impact the company's operational strategies [126]. - The company emphasizes the importance of project management and effective communication with regulatory bodies to mitigate risks associated with research and development progress [128]. - The company has not identified any new significant risk factors during the reporting period, indicating stable external and internal operating conditions [130]. Employee and Management Information - The total number of employees increased from 150 to 166, with a net addition of 57 employees during the reporting period [184]. - The company has implemented a comprehensive compensation system to enhance employee satisfaction and retention [185]. - The company organized over 120 training sessions in 2023 to enhance employee skills and compliance [186]. - The management team saw no changes during the reporting period, maintaining stability in leadership [178]. Legal and Compliance - The company has not faced any major litigation or arbitration cases that remain unresolved during the reporting period [135]. - The company has no overdue commitments that have not been fulfilled during the reporting period, and all ongoing commitments are being executed as planned [149]. - The company has strengthened its compliance awareness and aims to enhance the development of innovative drugs in the future [196].

一、拟续聘会计师事务所的基本情况 证券代码：430047 证券简称：诺思兰德 公告编号：2024-034 拟续聘 2024 年度会计师事务所公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 涉及会计师事务所提供的资料、信息，会计师事务所保证其提供、报送或披 露的资料、信息真实、准确、完整，不得有虚假记载、误导性陈述或者重大遗漏。 重要内容提示： 拟聘任的会计师事务所：中审亚太会计师事务所（特殊普通合伙） 服务及收费情况：中审亚太会计师事务所（特殊普通合伙）已为公司提供 7 年审计服务，上期审计收费 35 万元。本期审计费用未确定。 北京诺思兰德生物技术股份有限公司 （一）机构信息 公司拟聘任中审亚太会计师事务所（特殊普通合伙）为 2024 年年度的审计 机构。 1.基本信息 会计师事务所名称：中审亚太会计师事务所（特殊普通合伙） 成立日期：2013 年 1 月 18 日 组织形式：特殊普通合伙 注册地址：北京市海淀区复兴路 47 号天行建商务大厦 20 层 2206 首席合伙人：王增明 2023 年 ...

证券代码：430047 证券简称：诺思兰德 公告编号：2024-025 北京诺思兰德生物技术股份有限公司 2023 年度独立董事述职报告（王英典） 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担个别及连带法律责任。 本人作为北京诺思兰德生物技术股份有限公司（以下简称"公司"）的独立 董事，2023 年度，本人严格按照《公司法》、《证券法》、《上市公司独立董事 管理办法》及《北京证券交易所上市公司持续监管指引第 1 号——独立董事》等 有关法律、法规及《独立董事工作制度》和《公司章程》的相关规定和要求，认 真履行独立董事职责，及时了解公司的经营状况，按时出席公司召开的相关会议 并认真审议各项议案，对公司重大事项发表了独立意见，充分发挥了独立董事的 作用，切实维护了公司和全体股东特别是中小股东的合法权益。现将本人 2023 年履职情况报告如下： 2023 年任职期间，本人作为公司董事会薪酬与考核委员会委员， 积极参 与委员会的工作，在工作中严格按照相关规定的要求履行自己的职责，研究和 审查董事、高级管理人员的薪酬政策与方案，对 ...

关于第一期股权激励计划限制性股票第三个解除限售期解除限 售条件未成就暨回购注销相应部分限制性股票的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 北京诺思兰德生物技术股份有限公司（以下简称"公司"）于 2024 年 4 月 25 日召开第六届董事会第十次会议、第六届监事会第九次会议、第六届董事会 第二次独立董事专门会议，审议通过了《关于第一期股权激励计划限制性股票第 三个解除限售期解除限售条件未成就及关于回购注销部分限制性股票方案的议 案》，公司监事会、董事会薪酬与考核委员会及独立董事专门会议分别发表了核 查意见，上述议案尚需提交股东大会审议。 一、本次股权激励计划限制性股票的实施情况 2021 年 3 月 15 日，诺思兰德召开第五届董事会第九次会议，审议通过了《公 司第一期股权激励计划（草案）》《关于提请公司股东大会授权董事会办理股权 激励计划相关事宜》《关于提议召开公司 2021 年第一次临时股东大会》等议案。 2021 年 3 月 15 日，诺思兰德召开第五届监事会第六次会议，审议通过了《 ...

未成就及关于回购注销相应部分限制性股票方案的核查意见 证券代码：430047 证券简称：诺思兰德 公告编号：2024-039 北京诺思兰德生物技术股份有限公司 监事会关于回购注销部分限制性股票及注销部分股票期权的核 查意见 本公司及监事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 北京诺思兰德生物技术股份有限公司（以下简称"公司"）监事会，依据《中 华人民共和国公司法》《上市公司股权激励管理办法》《北京证券交易所股票上 市规则（试行）》《北京证券交易所上市公司持续监管指引第 3 号—股权激励 和员工持股计划》《北京证券交易所上市公司持续监管指引第 4 号—股份回购》 《公司章程》及公司《第一期股权激励计划（草案）》（以下简称"《激励计划》"） 等规章制度的有关规定，对公司《关于第一期股权激励计划限制性股票第三个解 除限售期解除限售条件未成就及关于回购注销相应部分限制性股票方案的议案》 《关于第一期股权激励计划股票期权第三个行权期行权条件、预留部分股票期权 第二个行权期行权条件未成就暨注销股票期权的议案》进行了核查 ...

一、2024 年度董事、监事及高级管理人员薪酬方案 证券代码：430047 证券简称：诺思兰德 公告编号：2024-036 北京诺思兰德生物技术股份有限公司 关于 2024 年度董事、监事、高级管理人员薪酬方案的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 北京诺思兰德生物技术股份有限公司（以下简称"公司"）于 2024 年 4 月 25 日召开第六届董事会第十次会议，审议了《关于 2024 年度董事薪酬方案的议 案》《关于公司 2024 年度高级管理人员薪酬方案的议案》；召开第六届监事会 第九次会议，审议了《关于 2024 年度监事薪酬方案的议案》,现将有关情况公告 如下： （2）独立董事、未在公司担任其他职务的非独立董事，职务津贴为 10 万 元/年（税前）。 （一）、适用对象 公司董事、监事及高级管理人员 （二）、适用期限 2024年 1 月 1 日-2024 年 12 月 31 日 （三）、薪酬标准 1、公司董事薪酬方案： 2、公司监事薪酬方案： （1）在公司担任其他职务的监事，根据其在 ...

Financial Performance - Operating revenue for the first quarter increased by 30.17% to ¥16,121,526.48 compared to the same period last year[11] - Net loss attributable to shareholders improved to ¥-12,250,307.09 from ¥-15,653,304.13 in the same period last year[11] - The net profit for Q1 2024 was reported at -¥11,280,541.80, an improvement compared to -¥15,153,590.93 in Q1 2023, reflecting a reduction in losses of about 25.5%[35] - The total comprehensive income for Q1 2024 was -¥11,521,154.71, an improvement from -¥15,471,427.08 in Q1 2023, representing a reduction in comprehensive losses of approximately 25.5%[35] - The total profit margin for Q1 2024 was -69.8%, an improvement from -127.5% in Q1 2023, reflecting a better cost management strategy[35] Assets and Liabilities - Total assets increased by 55.68% to ¥510,821,900.17 compared to the end of last year[11] - Total liabilities decreased to ¥101,732,174.67 from ¥131,496,996.06, a reduction of 22.6%[30] - Shareholders' equity rose significantly to ¥409,089,725.50, compared to ¥196,623,722.96, marking an increase of 108%[30] - Non-current assets totaled ¥278,665,242.54, up from ¥181,276,957.07, reflecting a growth of 53.7%[32] - Current liabilities decreased to ¥70,830,015.03 from ¥97,488,374.41, a decline of 27.3%[29] Cash Flow - Cash flow from operating activities improved to ¥-5,456,755.62 from ¥-6,283,074.74 in the same period last year[11] - Operating cash inflow for Q1 2024 was CNY 18,975,725.79, slightly up from CNY 18,845,432.31 in Q1 2023, reflecting a growth of 0.69%[38] - Net cash outflow from operating activities was CNY -5,456,755.62 for Q1 2024, an improvement compared to CNY -6,283,074.74 in Q1 2023, indicating a reduction of 13.14%[40] - The net increase in cash and cash equivalents for Q1 2024 was CNY 48,288,937.68, a significant recovery from a decrease of CNY -37,432,429.72 in Q1 2023[40] - The ending cash and cash equivalents balance for Q1 2024 stood at CNY 84,178,110.38, compared to CNY 111,680,498.41 at the end of Q1 2023[40] Share Capital and Equity - Net assets attributable to shareholders increased by 138.04% to ¥364,709,122.09 compared to the end of last year[11] - The total number of unrestricted shares increased from 164,000,356 to 165,396,029, representing a decrease in percentage from 63.38% to 60.17%[18] - The total number of restricted shares rose from 94,767,547 to 109,477,945, increasing the percentage from 36.62% to 39.83%[18] - The total share capital increased from 258,767,903 to 274,873,974 shares, reflecting an increase of 16,106,071 shares[19] - The company plans to issue 16,106,071 shares with a net amount of approximately 223,884,002.44 yuan, expected to be completed in January 2024[24] Investment and Income - Investment income increased by 188.34% to ¥391,509.54 due to interest income from structured deposits[13] - The company reported an investment income of ¥391,509.54 in Q1 2024, a significant increase from ¥135,780.83 in Q1 2023, marking a growth of approximately 187.5%[35] - Other income for Q1 2024 was recorded at ¥83,897.08, compared to ¥102,894.11 in Q1 2023, showing a decrease of about 18.5%[34] - The company experienced a foreign exchange gain of ¥202,872.26 in Q1 2024, compared to a gain of ¥33,287.67 in Q1 2023, indicating a substantial increase[35] Operational Efficiency - Total operating costs decreased slightly to ¥27,945,489.83 in Q1 2024 from ¥28,456,394.01 in Q1 2023, showing a reduction of about 1.8%[34] - Research and development expenses were ¥12,088,644.58 in Q1 2024, down from ¥13,449,259.47 in Q1 2023, indicating a decrease of approximately 10.1%[34]